Evidence map›Paper›PMID 39363054›Full record

ArticleTissue engineering and regenerative medicine2024

Exosomes-Shuttled lncRNA SNHG7 by Bone Marrow Mesenchymal Stem Cells Alleviates Osteoarthritis Through Targeting miR-485-5p/FSP1 Axis-Mediated Chondrocytes Ferroptosis and Inflammation.

Yue Wang, Kaili Hu, Changdi Liao, Ting Han, Fenglin Jiang, Zixin Gao, Jinhua Yan

Abstract read
In one paragraph

Article in Tissue engineering and regenerative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Long Non-Coding RNAsCurrent issues in molecular biology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yue WangRheumatology and Immunology Department, The First Hospital of Nanchang, No. 128, North Xiangshan Road, Nanchang, 330008, Jiangxi Province, China.
Kaili HuRheumatology and Immunology Department, The First Hospital of Nanchang, No. 128, North Xiangshan Road, Nanchang, 330008, Jiangxi Province, China.
Changdi LiaoRheumatology and Immunology Department, The First Hospital of Nanchang, No. 128, North Xiangshan Road, Nanchang, 330008, Jiangxi Province, China.
Ting HanRheumatology and Immunology Department, The First Hospital of Nanchang, No. 128, North Xiangshan Road, Nanchang, 330008, Jiangxi Province, China.
Fenglin JiangRheumatology and Immunology Department, The First Hospital of Nanchang, No. 128, North Xiangshan Road, Nanchang, 330008, Jiangxi Province, China.
Zixin GaoRheumatology and Immunology Department, The First Hospital of Nanchang, No. 128, North Xiangshan Road, Nanchang, 330008, Jiangxi Province, China.
Jinhua YanRheumatology and Immunology Department, The First Hospital of Nanchang, No. 128, North Xiangshan Road, Nanchang, 330008, Jiangxi Province, China. yanjinhua296@163.com.

Funding

Natural Science Foundation of Jiangxi Province 20212BAB206079Postdoctoral Science Foundation of China 2021M691346Postdoctoral Science Foundation of Jiangxi Province 2021RC14Science and Technology program of Jiangxi Province Health Commission 202211625
6 · The paper itself

Abstract

backgroundOsteoarthritis (OA), a degenerative joint disorder, is a major reason of disability in adults. Accumulating evidences have proved that bone marrow mesenchymal stem cells (BMSCs)-carried exosomes play a significant therapeutic effect on OA. However, the precise regulatory network remains unknown.

methodsOA and normal cartilage samples were acquired from patients, and chondrocytes were exposed to IL-1β to conduct a cellular OA model. Exosomes prepared from BMSCs were identified using nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Cell viability was determined with CCK-8 assay. Inflammatory injury was assessed by LDH and inflammatory factors (TNF-α and IL-6) using corresponding ELISA kits, respectively. Ferroptosis was evaluated by GSH, MDA and iron levels using corresponding kits, and ROS level with DCFH-DA. The expressions of genes/proteins were determined with RT-qPCR/western bolt. RNA immunoprecipitation and luciferase activity assay were conducted for testing the interactions of small nucleolar RNA host gene 7 (SNHG7)/ferroptosis suppressor protein 1 (FSP1) and miR-485-5p.

resultsThe expressions of SNHG7 and FSP1 were both reduced in IL-1β-induced chondrocytes and OA cartilage tissues, and there was a positive correlation between them in clinical level. Moreover, SNHG7 was enriched in BMSCs-derived exosomes (BMSCs-Exos) and could be internalized by chondrocytes. Functional analysis illustrated that BMSCs-Exos administration repressed inflammatory injury, oxidative stress and ferroptosis in IL-1β-induced chondrocytes, while these changes were reinforced when SNHG7 was overexpressed in BMSCs-Exos. Notably, FSP1 silencing in chondrocytes abolished the beneficial effects mediated by exosomal SNHG7.

conclusionsExosomal SNHG7 released from BMSCs inhibited inflammation and ferroptosis in IL-1β-induced chondrocytes through miR-485-5p/FSP1 axis. This work suggested that BMSCs-derived exosomal SNHG7 would be a prospective target for OA treatment.

Indexed as

ChondrocytesExosomesFerroptosisInflammationMesenchymal Stem CellsMicroRNAsOsteoarthritisRNA, Long NoncodingAnimalsHumansInterleukin-1betaMaleInterleukin-1betaMicroRNAsMIRN485 microRNA, humanRNA, Long NoncodingBone marrow mesenchymal stem cellsExosomesFerroptosisInflammationMiR-485-5p/FSP1OsteoarthritisSNHG7

Identifiers

PMID39363054
PMCPMC11589043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.